中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2014年
4期
10-12
,共3页
依维莫司%非小细胞肺癌%不良反应
依維莫司%非小細胞肺癌%不良反應
의유막사%비소세포폐암%불량반응
Everolimus%Non-small cell lung cancer%Adverse reaction
目的：观察依维莫司治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法选取2013年6月至2014年6月解放军总医院收治的晚期 NSCLC 患者18例，给予依维莫司口服或者联合化疗，直至疾病进展或不良反应难以耐受，观察疗效及不良反应。结果18例患者中完全缓解0例，部分缓解0例，稳定10例，进展2例，疾病控制率为55.5%，主要不良反应为口腔炎、咳嗽、腹泻，发生率分别为27.7%、16.6%、16.6%。结论依维莫司口服或者联合化疗可用于治疗晚期 NSCLC，且不良反应可耐受。
目的：觀察依維莫司治療晚期非小細胞肺癌（NSCLC）的臨床療效及不良反應。方法選取2013年6月至2014年6月解放軍總醫院收治的晚期 NSCLC 患者18例，給予依維莫司口服或者聯閤化療，直至疾病進展或不良反應難以耐受，觀察療效及不良反應。結果18例患者中完全緩解0例，部分緩解0例，穩定10例，進展2例，疾病控製率為55.5%，主要不良反應為口腔炎、咳嗽、腹瀉，髮生率分彆為27.7%、16.6%、16.6%。結論依維莫司口服或者聯閤化療可用于治療晚期 NSCLC，且不良反應可耐受。
목적：관찰의유막사치료만기비소세포폐암（NSCLC）적림상료효급불량반응。방법선취2013년6월지2014년6월해방군총의원수치적만기 NSCLC 환자18례，급여의유막사구복혹자연합화료，직지질병진전혹불량반응난이내수，관찰료효급불량반응。결과18례환자중완전완해0례，부분완해0례，은정10례，진전2례，질병공제솔위55.5%，주요불량반응위구강염、해수、복사，발생솔분별위27.7%、16.6%、16.6%。결론의유막사구복혹자연합화료가용우치료만기 NSCLC，차불량반응가내수。
Objective To evaluate the curative effect and adverse reactions of everolimus in advanced non-small cell lung cancer(NSCLS) patients. Methods From June 2013 to June 2014,18 caces of patients with advanced NSCLC were enrolled in this study in the Chinese PLA General Hospital. Everolimus (5-10 mg) was orally administered daily, some patients received chemotherapy at the same time, 21 days as a cycle. Results There were no patient who got complete or partial remission,10 cases whose condition were stable, 2 cases whose condition were disease progression,the disease control rate was 55.5%. The major adverse reactions of this study were stomatitis, cough and diarrhea , the incidence rate of them were 27.7%, 16.6% and 16.6% respectively. Conclusion Combined everolimus with or without chemotherapy are effective in the treatment of advanced NSCLC, and the adverse reactions are toleranted.
